Tredje AP fonden raised its position in shares of Johnson & Johnson (NYSE:JNJ) by 11.5% during the fourth quarter, Holdings Channel reports. The firm owned 455,689 shares of the company’s stock after buying an additional 46,839 shares during the period. Johnson & Johnson comprises 2.2% of Tredje AP fonden’s investment portfolio, making the stock its 2nd largest position. Tredje AP fonden’s holdings in Johnson & Johnson were worth $52,500,000 at the end of the most recent quarter.
Several other large investors have also bought and sold shares of JNJ. Itau Unibanco Holding S.A. purchased a new stake in Johnson & Johnson during the third quarter valued at about $104,000. Hefty Wealth Partners boosted its stake in Johnson & Johnson by 559.4% in the third quarter. Hefty Wealth Partners now owns 1,121 shares of the company’s stock valued at $132,000 after buying an additional 951 shares during the last quarter. Wechter Feldman Wealth Management Inc. purchased a new stake in Johnson & Johnson during the fourth quarter valued at about $209,000. New Capital Management LP purchased a new stake in Johnson & Johnson during the fourth quarter valued at about $214,000. Finally, Turner Investments LLC purchased a new stake in Johnson & Johnson during the fourth quarter valued at about $218,000. Hedge funds and other institutional investors own 65.30% of the company’s stock.
Johnson & Johnson (NYSE:JNJ) opened at 128.07 on Tuesday. Johnson & Johnson has a one year low of $106.36 and a one year high of $129.00. The firm has a market capitalization of $347.50 billion, a PE ratio of 21.59 and a beta of 0.74. The stock’s 50 day moving average price is $119.96 and its 200 day moving average price is $117.07.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, January 24th. The company reported $1.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.56 by $0.02. The firm earned $18.10 billion during the quarter, compared to the consensus estimate of $18.28 billion. Johnson & Johnson had a return on equity of 25.61% and a net margin of 22.78%. The business’s revenue for the quarter was up 1.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.44 EPS. Analysts expect that Johnson & Johnson will post $7.04 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, March 14th. Shareholders of record on Tuesday, February 28th were paid a $0.80 dividend. The ex-dividend date of this dividend was Friday, February 24th. This represents a $3.20 dividend on an annualized basis and a yield of 2.50%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 54.42%.
Your IP Address:
Several equities research analysts recently issued reports on JNJ shares. Vetr cut Johnson & Johnson from a “hold” rating to a “sell” rating and set a $119.73 price objective on the stock. in a report on Tuesday, March 7th. Zacks Investment Research cut Johnson & Johnson from a “hold” rating to a “sell” rating in a report on Tuesday, January 3rd. Barclays PLC cut Johnson & Johnson from an “overweight” rating to an “equal weight” rating and lowered their price objective for the stock from $130.00 to $125.00 in a report on Tuesday, November 29th. They noted that the move was a valuation call. Bank of America Corp reiterated a “hold” rating and issued a $126.00 price objective on shares of Johnson & Johnson in a report on Monday, November 28th. Finally, Wells Fargo & Co cut Johnson & Johnson from an “outperform” rating to a “market perform” rating and lifted their price objective for the stock from $112.28 to $112.80 in a report on Thursday, January 26th. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and six have assigned a buy rating to the company. Johnson & Johnson presently has a consensus rating of “Hold” and an average price target of $124.09.
In other Johnson & Johnson news, VP Paulus Stoffels sold 22,000 shares of the company’s stock in a transaction on Wednesday, February 15th. The stock was sold at an average price of $117.29, for a total value of $2,580,380.00. Following the completion of the transaction, the vice president now owns 127,650 shares in the company, valued at approximately $14,972,068.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.11% of the stock is owned by corporate insiders.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.